Skip to main content
. 2011 Apr 25;6(4):e18989. doi: 10.1371/journal.pone.0018989

Figure 1. Both FL-L1CAM and SV-L1CAM were expressed in benign and malignant tumours of human ovarian carcinoma patients.

Figure 1

Expression of FL-L1CAM (A) and SV-L1CAM mRNA (B) was analyzed in benign and malignant ovarian tumours and their peritoneal metastases. Mean of relative target gene mRNA vs. 18S rRNA ± SEM: A. Values obtained for FL-L1CAM; benign tumours: 1.85±0.85, n = 2; FIGO I: 0.73±0.49, n = 5; FIGO III or FIGO IV: 5.30±2.53, n = 7; metastases: 2.57±1.37, n = 12 (p = 0.664, as determined by Kruskal-Wallis One Way ANOVA on Ranks). B. Values obtained for SV-L1CAM; benign tumours: 4.99±3.99, n = 2; FIGO I: 17.33±10.41, n = 5; FIGO III or FIGO IV: 189.13±63.25, n = 5; metastases: 240.21±51.18, n = 8 (all groups: *p = 0.015, as determined by Kruskal-Wallis One Way ANOVA on Ranks and subsequent post hoc comparison using Holm-Sidak method; pairwise comparisons (unadjusted p values): FIGO I vs. benign: p = 0.903; FIGO III or FIGO IV vs. benign: p = 0.084; metastases vs. benign: *p = 0.024; FIGO III/IV vs. FIGO I: *p = 0.037; metastases vs. FIGO I: **p = 0.005; metastases vs. FIGO III/IV: p = 0.465).